Pregnancy is generally considered to be an immunosuppressed state; however, the impact of pregnancy on mothers with viral hepatitis (Table 1 ) and the impact of viral hepatitis on fetuses/infants ( Table 2) are not the same for all types of hepatitis.
Pregnant women with acute hepatitis due to hepatitis E virus (HEV) or herpes simplex virus (HSV) have an increased risk of acute liver failure compared to persons who are not pregnant. Flares of chronic hepatitis B may occur during pregnancy and in the postpartum period, but hepatic decompensation is rare.
The risk of vertical transmission of hepatitis viruses is higher in pregnant women with acute versus chronic infection. In general, the risk is not increased with amniocentesis, fetal monitoring, or vaginal birth, and cesarean should not be recommended to prevent transmission of hepatitis viruses. 1 Breastfeeding is safe for women with chronic hepatitis B virus (HBV) or chronic hepatitis C virus (HCV) infections-unless they have cracked nipples. 2, 3 Hepatitis A and B vaccines are safe to be administered during pregnancy.
Hepatitis A Virus
Hepatitis A virus (HAV) infection does not progress to chronic infection, and HAV is generally transmitted via fecal-oral route; therefore, maternal-infant transmission is rare. The highest risk of gestational complications such as premature rupture of membrane, placental separation, or preterm labor is during the second half of pregnancy (Table 1) .
Hepatitis B Virus
Neither acute nor chronic hepatitis B virus (HBV) infection poses a risk to fetal development. Flares of chronic hepatitis B had been reported during pregnancy and in the postpartum period. These flares are usually mild and in some instances may be accompanied by the spontaneous loss of hepatitis B e antigen (HBeAg). 5 In the absence of prophylaxis, the risk of vertical transmission is up to 90%. 6 The risk is higher if the mother is HBeAg-positive or has high serum HBV DNA levels. Perinatal transmission of HBV results in chronic infection in 90% of infants; therefore, screening of all pregnant women for hepatitis B surface antigen (HBsAg) at the first antenatal visit to identify those who test positive is critical. As of 2012, 181 countries worldwide have adopted universal HBV vaccination (regardless of maternal HBsAg status) for all newborns. In most countries, babies born to HBsAgpositive mothers will additionally receive one dose of hepatitis B immune globulin (HBIG) at a different site from the first dose of HBV vaccine within 12 hours of birth. Passiveactive prophylaxis reduces the incidence of maternal-infant transmission of HBV to 5% to 10%. The infant should be tested for HBsAg and antibody to HBsAg 1 to 2 months after completing the vaccine series to confirm immunity and to rule out infection.
High maternal serum HBV DNA is a major cause of prophylaxis failure. Administration of an oral antiviral to mothers with high serum HBV DNA during the third trimester of pregnancy has been shown to decrease the incidence of prophylaxis failure (Table 3) . Lamivudine was used in most studies but is a pregnancy class C drug, whereas telbivudine and tenofovir are pregnancy class B drugs. Data in the antiretroviral registry showed that the use of lamivudine and tenofovir during pregnancy, even in the first trimester, did not result in an increased incidence of birth defects. Although the antiviral drug is used for a short duration in this setting, given the high HBV DNA levels, tenofovir is preferred to minimize the risk of antiviral drug resistance. There is no consensus on when to initiate, when to discontinue, or what cutoff HBV DNA level should be used to initiate antiviral therapy. Most experts agree that antiviral therapy should be considered when maternal HBV DNA is > 7 to 8 log 10 IU/mL, and treatment should be started around week 28 to 32 of pregnancy to allow time for the virus to be suppressed. Treatment may be stopped after delivery if the goal of antiviral therapy is to decrease the incidence of perinatal transmission. Tenofovir is a prodrug, and the concentration in breast milk is 4.7% of that in serum. 7, 8 Limited data suggest that breastfeeding is permissible for mothers receiving tenofovir. Hepatitis flares may occur after antiviral therapy is discontinued, and the mothers should be closely monitored for 6 months after treatment is stopped. Fig. 1 shows an algorithm for managing women with chronic HBV infection who are contemplating pregnancy. Prior to pregnancy, pegylated interferon (PEG-IFN) may be considered because of its finite duration. Among the oral antivirals, tenofovir is the preferred drug because of its high barrier to resistance and demonstrated safety in pregnancy.
Hepatitis C Virus
Vertical transmission of hepatitis C virus (HCV) occurs in approximately 5% of newborns born to HCV-infected mothers; the risk is higher if the mother is coinfected with HIV 9 or has high HCV RNA level. Diagnosis of HCV infection in the infant can be performed by testing for HCV RNA. If HCV antibody (anti-HCV) is tested, it should be delayed until the infant is at least 12 months of age.
1 Approximately 60% to 80% of infected infants will develop chronic infection. Treatment of HCV should not be offered during pregnancy because ribavirin is a pregnancy class X drug that is highly teratogenic, and interferon is a class C drug. There are no data on safety of direct-acting antiviral agents in pregnancy. Currently, there is no means to prevent maternal-infant transmission of HCV.
Hepatitis E Virus
Hepatitis E virus (HEV) is usually spread via fecal-oral route; however, ingestion of undercooked pork or exposure to boar or wild pigs had also been reported to be a source of HEV infection in developed countries.
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Acute hepatitis E is self-limiting in the vast majority of cases, but hepatitis E during pregnancy can cause severe hepatitis and acute liver failure, especially when it occurs in the third trimester. Maternal fatality of 16% to 20% had been reported when hepatitis E occurs in the third trimester of pregnancy 12, 13 and is caused by acute liver failure, eclampsia, or hemorrhage. A vaccine has been developed for hepatitis E, but it is not available in most countries.
Herpes Simplex Virus
Herpes simplex virus (HSV) infection during pregnancy is rare but can cause disseminated infection, HSV hepatitis, and acute liver failure, especially when the infection occurs in the third trimester of pregnancy. Primary as well as latent HSV infection-and both HSV-1 and HSV-2-can cause hepatitis and acute liver failure. Patients typically present with fever and markedly elevated aminotransferases. Skin 
